Neuroscience

Doctor examining brain MRI
#FSD Pharma #Lucid Psycheceuticals #Multiple sclerosis #Neuroscience #Phase I trial

New drug candidate for MS shows promise in Phase I trial

FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,”… Read More

#News

Laboratory equipment
#Expansion #Gate Neurosciences #Lab space #Major depressive disorder #Neuroscience

Gate Neurosciences expands research operations

Gate Neurosciences has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois. The company hopes to further build the translational biomarker data package supporting its NMDA receptor modulator portfolio and advance foundational mechanism insights behind its synaptic function-enhancing molecules. Read More

#News

Amygdala
#Anxiety disorder #Drug discovery #Neuroscience #Preclinical investigations #University of Bristol #University of Exeter

Discovery represents the ‘first step’ to better anti-anxiety drugs

A team of scientists have discovered that modification of a gene in the brain can reduce anxiety levels, offering an exciting novel drug target for anxiety disorders. The discovery, led by researchers at the Universities of Bristol and Exeter in the UK, is published in Nature… Read More

#News

#Alzheimer's #Biomarkers #Digital biomarkers #Neurodegenerative disorders #Neuroscience

Why digital biomarkers will power tomorrow’s Alzheimer’s therapies

Listen to this article on the DDW Podcast: Rivka Kreitman, CIO of NeuraLight explores the landscape of therapies for Alzheimer’s and explains why digital biomarkers are key to combatting the disease. Neurodegenerative diseases – the collection of progressive conditions characterised by neuron cell damage and death and subsequent loss of motor… Read More

#Exclusive Content

Covid/neuroscience concept
#AI / data analytics / healthtech / informatics #Drug discovery #Neuroscience

DDW Spring issue out now

The Spring 2023 issue of Drug Discovery World Magazine is out now. Featuring a Therapeutic Spotlight on Neuroscience, the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Key features of the… Read More

#Editor's Choice #News

Female medical researcher
#Genetics #Genetics / genomics #Icahn School of Medicine #Neuroscience #Psychiatry #Schizophrenia

Researchers identify genes that may increase schizophrenia risk

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-centre study further demonstrated that the schizophrenia risk conferred by these… Read More

#News

#Biotechnology #Drug development #Neurodegenerative disorders #Neuroscience #Seed funding

€28M for neurodegenerative disease treatments

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable… Read More

#Business & Investment #News

#Anxiety disorder #Biotherapeutics #Neuroscience #Postpartum depression

Potential treatment for anxiety and postpartum depression 

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the… Read More

#News

Neurons in Parkinson's disease
#Genetics / genomics #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's #University of Queensland

Focus on autophagy could lead to more effective Parkinson’s drugs

Researchers have identified that a gene associated with an increased risk of Parkinson’s Disease also contributes to a build-up of cell debris in the brain. Dr Adekunle Bademosi from The Queensland Brain Institute said the discovery could change the focus of Parkinson’s Disease treatment. Without the… Read More

#News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Brain #Gut microbiome #Mouse models #Neurology #Neuroscience

Mouse study findings suggest new approach to treating Alzheimer’s 

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.  Context   Researchers at Washington University School of Medicine in St Louis showed that… Read More

#News

MRI showing glioblastoma
#Brain #Cancer research #Drug repurposing #Neuroscience #Oncology

FDA-approved drug sensitises brain cancer cells to radiotherapy

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.  Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.  GBM is a… Read More

#Cancer Research #News

Patient speaking to psychiatrist
#Alta Neuroscience #Biomarkers #Major depressive disorder #Neuroscience #Phase II trial #Precision psychiatry #Psychiatry

Precision drug could redefine depression treatment

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More

#News

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News